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Background: Etomidate frequently induces myoclonus when administered intravenously with bolus injection during 
anesthetic induction. This can be bothersome for the anesthesiologist. The dose of remifentanil appropriate for 
preventing myoclonus without side effects was investigated.
Methods: All patients with American Society of Anesthesiologists (ASA) physical status I-III were divided into three 
groups (n = 33 per group) according to the pretreatment effect site concentration of remifentanil (Ultiva, Glaxo-
Wellcome, München, Germany) of 0, 2 or 4 ng/ml (Group N: 0 ng/ml, Group R: 2 ng/ml, Group Q: 4 ng/ml) by a target 
controlled infusion (TCI) system. After a 0.3 mg/kg dose of etomidate was injected intravenously for over 1 minute 
for anesthetic induction, myoclonus was observed. Before the etomidate injection, the patients were pretreated with 
remifentanil and their side effects were monitored.
Results: The number of patients showing myoclonus was significantly different among the groups. The incidence of 
myoclonus was 81%, 12% and 0% (groups N, R, and Q, respectively, P < 0.01). Side effects including bradycardia and 
hypotension did not occur in either Group R or Q. Chest wall rigidity occured in 45% of patients in Group Q.
Conclusions: Administration with a 2 ng/ml effect site concentration of remifentanil could reduce the incidence of 
myoclonus caused by etomidate bolus injection without chest wall rigidity. (Korean J Anesthesiol 2011; 61: 127-132)
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Introduction 
    Etomidate is a popular hypnotic agent, and it has a stable 
hemodynamic profile with minimal histamine release [1]. 
However, etomidate often induces spontaneous movements, 
especially myoclonic activity, and can enhance focal 
epileptogenic activity in patients with epilepsy [2]. Myoclonus 
has been described as the involuntary contracture of some 
muscle fibers, which involves a whole muscle, or different 
muscles of one group, leading to short observable movements 
of the corresponding body parts. Myoclonus is observed 
in 50-80% of non-premedicated patients after etomidate 
administration [3], and it can be a problem in patients who 
had open-global injury or full-stomach conditions. In patients 
with an open-global injury, myoclonus after etomidate 
administration increases the risk of vitreous prolapse because 
of high intraocular pressure [4].
    The incidence of myoclonus can be reduced by various 
agents including benzodiazepines, magnesium sulfate, 
rocuronium and opioids [1,4-7]. Remifentanil is a selective 
μ-receptor agonist with similar pharmacodynamic properties 
to other opioid receptor agonists such as fentanyl [8,9], and 
it is metabolized rapidly with a very short acting duration 
independent of infusion time. However, it can cause adverse 
effect like bradycardia and/or chest wall rigidity even at the low 
dose of 1.0 μg/kg [8,10-12].
    The aim of this study was to investigate the safe effect site 
concentration of remifentanil for preventing myoclonus 
induced by etomidate injection without generating side effects.
Materials and Methods
    The study protocol was approved by the Institutional Review 
Board of the Clinical Research Ethics Committee. Adult patients 
with American Society of Anesthesiologists (ASA) physical 
status I-III and who were scheduled for elective surgery under 
general anesthesia were selected for this study and the three 
groups were demographically similar (Table 1). Patients with 
neuropsychological disease or abnormality of the adrenal gland 
were excluded. Thirty minutes before Committee. Adult patients 
with American Society of Anesthesiologists (ASA) physical 
status I-III and who were scheduled for elective surgery under 
general anesthesia were selected for this study and the three 
groups were demographically similar (Table 1). Patients with 
neuropsychological disease or abnormality of the adrenal gland 
were excluded. Thirty minutes before arrival at the operating 
room, midazolam 0.05 mg/kg and glycopyrrolate 0.2 mg were 
injected intramuscularly as premedication. Venous access with 
an IV canula was placed in the patient’s antecubital fossa. On 
arrival at the operating room, patient monitors such as oxygen 
saturation (SpO2) by pulse oximeter probe, electrocardiography 
(ECG), and a blood pressure cuff were applied. The standard 
bispectral index (BIS) was monitored (BIS Quatro,Aspect 
Medical System Inc.) by placing the electrode on the forehead 
of each patient and the BIS score was monitored.
    The patients, who had provided written, informed consent, 
were allocated in a randomized fashion by sealed envelope 
into the 3 pretreatment groups (n = 33 per group) according 
to the effect site concentration of remifentanil (Ultiva, Glaxo-
Wellcome, München, Germany) of 0, 2 or 4 ng/ml (Group 
N: 0 ng/ml, Group R: 2 ng/ml, Group Q: 4 ng/ml). A target 
controlled infusion (TCI) system for remifentanil was adopted 
to produce an accurate desired plasma concentration. Each 
effect site concentration (2 or 4 ng/ml) was set by an infusion 
pump (Orchestra
Ⓡ, Fresenius Vial, France) with the Minto 
model. The concentration of 0 ng/ml of remifentanil was set 
by a syringe filled with saline. BP and HR were recorded at 
baseline, 210 seconds after injection of etomidate 0.3 mg/
kg, 30 seconds, 1 min and 3 min after intubation. When the 
SQI (signal quality index) was maintained over 90, the BIS 
was measured continuously throughout the procedure and 
recorded at baseline, the end of etomidate administration, 
and every 30 seconds after etomidate administration until 2 
minutes. After preoxygenation for 1 minute, one of the solutions 
(remifentanil 50 μg/ml or saline) was infused through the 
infusion pump. Any side effects, such as cough, sedation, chest 
wall rigidity, or apnea, were checked by an anesthesiologist 
who was blinded to the groups. The Ramsay sedation scale 
was used for evaluating sedation and sedation was indicated 
by a 4 on the Ramsay sedation scale, which was no response 
Table 1.  Demographic Data
 
Group N  
(n = 33)
Group R  
(n = 33)
Group Q  
(n = 33)
Age (yr)
Gender (M/F)
Weight (kg)
41.9 ± 16.7
17/16
65.4 ± 12.4
44.2 ± 15.0
16/17
62.8 ± 10.9
42.2 ± 18.3
16/17
65.3 ± 13.2
Group N: normal saline, Group R: pretreatment with 2 ng/ml of 
remifentanil, Group Q: pretreatment with 4 ng/ml of remifentanil.
Table 2.  Ramsay Sedation Scale
Score Response
1
2
3
4
5
6
Anxious or restless or both
Cooperative, orientated and tranquil
Responding to commands
Brisk response to stimulus
Sluggish response to stimulus
No response to stimulus
Sedation was indicated by 4 on the Ramsay sedation scale.129 www.ekja.org
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to commands (Table 2). Chest wall rigidity was defined as 
decreased chest wall compliance to external positive ventilatory 
pressure. During ventilation with a mask, chest wall rigidity 
was monitored for improper ventilation and the increase 
of peak inspiratory pressure above 20 mmHg [13]. After the 
effect-site concentration of remifentanil reached the target 
concentration, 0.3 mg/kg of etomidate (Etomidate-Lipuro, 
B. Braun Melsungen, Melsungen, Germany) was injected 
intravenously for over 1 min, then patients were observed 
visually for myoclonus. When myoclonus is present, its severity 
was graded by an anesthesiologist who was blinded to the 
effect site concentration of remifentanil. Intensity of myoclonic 
movement was graded as 0 (none), 1 (mild; movement at the 
finger or wrist only), 2 (moderate; involving the face and leg), 
or 3 (severe; generalized response or fast abduction of the limb) 
[8,11]. Two minutes after etomidate administration, rocuronium 
0.8 mg/kg was administered to facilitate tracheal intubation. 
After ventilation with 6 vol% sevoflurane for 90 seconds, an 
endotracheal tube was intubated. 
    The expected incidence of myoclonus in the control group 
(Group N) was 80% and 28 patients were required in each 
group to detect a 50% difference at a 95% significance level 
and a power of 0.8 based on previous studies [1,3]. Thirty three 
patients were included in each group. Statistical analysis was 
performed by SPSS 12.0 (SPSS, Chicago, IL). Comparison of 
demographic data was performed by one way ANOVA and 
the chi-square test. The incidence and severity of myoclonus 
were analysed by Pearson's chi-square test and linear by linear 
association. The changes in BP and HR over time were analyzed 
by repeated measures ANOVA. Results were considered 
statistically significant when P < 0.05.
Results 
    The incidence of myoclonus of each group was significantly 
different according to the Pearson chi-square test (P < 0.01). 
The incidence of myoclonus in Groups N, R, and Q were 
81%, 12%, and 0%, respectively (P < 0.01) (Table 3). The 
severity of myoclonus decreased with an increasing effect 
site concentration of remifentanil, which was revealed by the 
linear by linear association. Cough (13/33 patients), chest wall 
rigidity (15/33 patients), apnea (2/33 patients), and sedation 
(15/33 patients) occurred in Group Q. No side effects occurred 
Table 3. Frequency and Severity of Myoclonus after Injection of 
Etomidate Numbers are Frequencies
  Group   N Group   R Group   Q
None
Mild
Moderate
Severe
6
6
9
12
29
3
1
0
33
0
0
0
Group N: normal saline, Group R: pretreatment with 2 ng/ml of 
remifentanil, Group Q: pretreatment with 4 ng/ml of remifentanil.
Table 4. Number of Side Effects
 
Group N  
(n = 33)
Group R  
(n = 33)
Group Q  
(n = 33)
Cough (n)
Chest wall rigidity (n)
Apnea (n)
Sedation (n)
0
0
0
0
0
0
0
0
13
15
2
2
Chest wall rigidity was evaluated by improper ventilation and an 
increase in peak inspiratory pressure over 20 mmHg during mask 
ventilation. Sedationindicates a 4 on the Ramsay sedation scale. 
Group N: normal saline, Group R: pretreatment with 2 ng/ml of 
remifentanil, Group Q: pretreatment with 4 ng/ml of remifentanil.
Fig. 1. The change of BP (A) and HR (B) in Group R and Group Q were lesser than that in Group N, and BP was lower in Group R and Group 
Q than Group N. Group N: normal saline, Group R: pretreatment with 2 ng/ml of remifentanil, Group Q: pretreatment with 4 ng/ml of 
remifentanil. *P < 0.05 compared to the other group.130 www.ekja.org
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in groups N or R (Table 4). The changes of BP throughout the 
procedure did not differ among the groups except for the post-
intubation period. BP after intubation in Group N was higher 
than BP in the other groups (P < 0.05) (Fig. 1). Even though it 
looks like there were differences in HR between groups, there 
was no significant difference in statistics. 
Discussion
    This study showed that a 2 ng/ml effect site concentration of 
remifentanil prevented etomidate-induced myoclonus without 
any side effects. The incidence of myoclonus was 82% in Group 
N and it decreased to 12% in group R. We could not find any 
myoclonus in Group Q. We could compare the effect site 
concentration in each case using TCI. TCI allows an accurate 
adaptation of the analgesia level and fewer overdose-linked 
adverse effects. This result is compatible with previous reports 
utilizing other treatment [1,3,4]. Myoclonus occurred at least 60 
seconds to 90 seconds after the end of injection and no patients 
expressed pain during injection. Thus we defined myoclonus 
differently from injection pain based on those results. Some 
studies have reported that 50 to 80% of patients receiving 
etomidate showed myoclonic activity [3,14]. 
    The neurologic mechanism of myoclonic activity after 
etomidate administration is not clear, but may be a kind of 
seizure activity [14]. Other studies suggested that myoclonus 
after etomidate administration is a result of temporary sub-
cor  tical disinhibition like that of restless legs during sleep and 
does not happen from an epileptic focus [3,15,16]. An unsyn-
chronized onset of etomidate induces fast depression of the 
cortex, resulting in temporary disinhibition of the subcortex 
from inducing the myoclonic movement. Thus, pretreatment 
with a small amount of etomidate reduces myoclonus and this 
suggests a support for the former mechanism [3].
    The dosage of etomidate influences the incidence of 
myocluonus. The dosage as much as 0.05 mg/kg etomidate did 
not induce myoclonic activity, but a dosage above 0.075 mg/kg 
caused myoclonic activity in men [3]. 
    Schwarzkopf et al. [1] suggested that midazolam (0.5 mg/kg), 
injected 90s before etomidate administration intravenously, 
reduced the incidence of myoclonus by 20%. In control group 
of this study, however, midazolam (0.05 mg/kg) injected 
intramuscularly 30 minutes before etomidate administration 
did not reduce the incidence of myoclonus. The incidence of 
control group was 82% which was not differ from previously 
reported myoclonus incidence. The different results may 
stem from the dosage of midazolam and the route and timing 
of injection. Magnesium sulfate (2.48 mmol) injected 90 s 
before etomidate administration intravenously, reduced the 
incidence of myoclonus by 76% and severity of myoclonus 
[5]. Pretreatment of etomidate could reduce the incidence of 
myoclonus. It was suggested that myoclonus after injection of 
0.3 mg/kg etomidate was less likely after pretreatment with 0.03 
or 0.05 mg/kg etomidate than after pretreatment with 0.075 
mg/kg etomidate both in men and women [3]. Pretreatment of 
rocuronium (0.06 mg/kg) showed the incidence to be 25% [6]. 
    Opioids could reduce the incidence of etomidate induced 
myoclonus. Pretreatment with alfentanil (5 μg/kg) resulted in 
an incidence of 25% [17] and fentanyl (100, 250, and 500 μg/kg) 
before etomidate injection reduced the incidence of myoclonus 
(33%, 13%, and 0%, respectively) but increased the incidence 
of apnea (87%, 87%, and 100%, respectively) [18]. Hueter et al. 
[4] showed that in female patients, there were no patients who 
had myoclonic activity in the group premedicated with 0.3 mg/
kg sufentanil, but 80% of patients in the placebo group showed 
myoclonic activity.
    Recently, remifentanil, which is a short-acting opioid, has 
been suggested for possibly reducing myoclonus after etomi-
date injection [19]. There was no study about the me  chanism 
of remifentanil to reduce etomidate-induced myoclonus. The 
mechanism of fentanyl, which has similar potency, is that it 
stimulates GABA Aμ-opioid receptors in the basal ganglia [3]. 
These reports are similar to ours that increasing the dose of 
opioids decreases the incidence of myoclonus but it increases 
the side effects of cough and chest wall rigidity. We could 
find that the side effects of remifentanil increase in Group 
Q (remifentanil 4 ng/ml). The recommended loading bolus 
dose of remifentanil during induction with a hypnotic agent 
is 1.0 μg/kg [10]. Hwang et al. [20] studied pre-treatment of 
remifentanil: Without premedication, they injected 1.0 μg/
kg remifentanil for over 60 s, then etomidate injection for over 
10 s, then had a 2-min observation period for myoclonus. In 
that study, myoclonus occurred in 17% of cases with 1.0 μg/
kg of remifentanil and a similar incidence with 0.05 mg/kg 
pre-treatment with midazolam, but chest wall rigidity and 
bradycardia occurred. Muscle rigidity and bradycardia were 
serious side-effects of remifentanil [8-10,21].
    We cannot ensure that remifentanil is a superior agent to 
other drugs or opioids, but it is advantageous that remifentanil 
has a rapid onset and offset, it is easy to adjust the proper effect 
site concentration and to find the safety concentration when 
using a TCI system. Further evaluation comparing other agents 
with 2 ng/ml of remifentanil is needed in the future.
    There is a limitation in the design of our study, in that 
we infused etomidate immediately after the effect site 
concentration of remifentanil reached target concentration. 
    Our study was planned with premedication with glycopyrro-
late and midazolam to decrease upper airway secretion and for 
ethical reasons. We thought premedication with midazolam 
would have a synergic effect with remifentanil. In other studies, 131 www.ekja.org
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when premedication is given with benzodiazepine or fentanyl, 
myoclonus is reduced by inhibition of subcortical neuronal 
activity [22,23].
    In the case of this study, it was performed with a TCI pump 
to titrate the effect site concentration of remifentanil. In the 
absence of a TCI pump, a cautious bolus injection could be a 
substitution for the pump infusion. The effect site concentration 
of 4-6 ng/ml of remifentanil could be achieved by a bolus dose 
of 0.8-2.1 μg/kg if adjusted according for various ages and body 
weights [24]. The maximal time to the effect site concentration 
was about 70-100 seconds. Fifteen patients in Group Q ex-
perienced chest wall rigidity. In Group R, the incidence of chest 
wall rigidity was significantly decreased and there was no other 
side effect.
    Opioid administration during induction has often been 
complicated by muscular rigidity and difficult ventilation. The 
sequelae of difficult ventilation are clinically important and can 
include hypertension, hypoxemia, pulmonary hypertension, 
respiratory acidosis, and increased intracranial pressure [25-
27]. Difficult or impossible ventilation after opioid induction is 
commonly ascribed to rigidity of the abdominal and thoracic 
musculature. There has been some evidence that fiber optic 
visualization of the glottis revealed closed vocal cords in some; 
however, they also described patients who had opened vocal 
cords but could not be ventilated [28]. The incidence of rigidity 
and severities varies depending on the kinds of opioid and 
doses used and the rate at which it is administered. To avoid 
serious airway obstruction like glottic closure, cautious dosing 
and administration must be carried out. In the case of our 
study, normal ranges of end tidal carbon dioxide showed there 
were no cases of airway obstruction. 
    This study has a limitation in defining the chest wall rigidity 
with peak air way pressure. To obtain accurate measurements of 
peak airway pressure, an unintubated mask ventilation requires 
an excellent mask seal, proper placement of an oral airway, and 
the use of an aggressive jaw thrust maneuver. Delivering a tidal 
volume with pressure above 20 mmHg, which is considered 
to be the upper esophageal sphincter tone is prone to cause 
abdominal distension. We tried not to raise peak airway 
pressure above 20 mmHg; if it happened, it was considered as 
occurrence of chest rigidity.
    We can conclude that treatment with remifentanil 2 ng/ml of 
effect site concentration before etomidate administration signi-
ficantly reduced the frequency of myoclonic activity without 
side effects. 
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